Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drug Allergy Clear all
Completed Not applicable Interventional Results available

Asthma Link: A Real World Application of School Supervised Asthma Therapy

NCT04942379
View directory record Official record
Conditions
Childhood Asthma
Interventions
Asthma Link, Enhanced Usual Care
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
6 Years to 17 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951
View directory record Official record
Conditions
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
3 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Not applicable Interventional Results available

Symptom Perception

NCT03646669
View directory record Official record
Conditions
Asthma
Interventions
PEF Feedback, Asthma education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis

NCT00432757
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Los Angeles, California • Charlotte, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2009 · Synced Oct 30, 2026, 7:45 PM EDT
Completed No phase listed Observational

Complementary and Alternative Medicine Use in Low-Income African American and Caucasian Adults With Asthma

NCT00094419
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Oct 30, 2026, 7:45 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

NCT04262791
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Wrist Actigraphy Device, Sleep Headband
Device
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Orlando, Florida • Grayslake, Illinois • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction

NCT07217613
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
silk fibroin-based incision dressing, cyanoacrylate-based closure system
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
14 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 7:45 PM EDT
Completed No phase listed Observational

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

NCT03860376
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Phase 4 Interventional

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118690
View directory record Official record
Conditions
Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions
Fluticasone propionate/salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 17 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Jonesboro, Arkansas • East Artesia, California • Huntington Beach, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 7:45 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Cyclosporine Vs Steroids in DRESS

NCT04988256
View directory record Official record
Conditions
DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions
Cyclosporine, Methylprednisolone and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 30, 2026, 7:45 PM EDT
Terminated Phase 2 Interventional Results available

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

NCT00751101
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
Interventions
Nicotine patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma

NCT03860519
View directory record Official record
Conditions
Asthma
Interventions
Electronic Medication Monitors on ICS and SABA - Active Mode, Electronic Medication Monitors on ICS and SABA - Silent Mode, Asthma App Tracking of ICS/SABA Usage - Active Mode, Asthma App Tracking of ICS/SABA Usage - Silent Mode, NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes, NorthShore Connect Real Time ICS and SABA Usage Feedback - No, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No
Behavioral
Lead sponsor
Endeavor Health
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 30, 2026, 7:45 PM EDT
Not yet recruiting Phase 1 Interventional

Subconjunctival Humira for Boston Keratoprosthesis

NCT06926478
View directory record Official record
Conditions
Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions
Adalimumab Injection
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

NCT01545453
View directory record Official record
Conditions
Asthma
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 7:45 PM EDT
Not yet recruiting No phase listed Observational

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

NCT07613216
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions
Not listed
Lead sponsor
Cosmos Rx, Inc
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Not applicable Interventional Results available

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

NCT02521363
View directory record Official record
Conditions
Breast Cancer
Interventions
KIBUR MICRODEVICE, anthracycline and taxane based chemotherapy
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 30, 2026, 7:45 PM EDT
Not listed Phase 4 Interventional

Inpatient Penicillin Delabeling for Low-Risk Patients

NCT06414694
View directory record Official record
Conditions
Penicillin, Drug Allergy
Interventions
Direct Oral Challenge
Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
2 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 7:45 PM EDT
Completed No phase listed Observational

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

NCT00557180
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Beclomethasone dipropionate HFA, Tiotropium bromide, Salmeterol xinafoate
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 7:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions
Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
63
States / cities
Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 7:45 PM EDT
Withdrawn Phase 4 Interventional

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

NCT02163005
View directory record Official record
Conditions
Contrast Media Allergy
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
56 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 30, 2026, 7:45 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

NCT01782703
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
0 Months to 17 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Northbrook, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 7:45 PM EDT
Recruiting No phase listed Observational

Brain Slice Explants to Predict Drug Response in Brain Tumors

NCT05978557
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
Biospecimen collection
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 7:45 PM EDT
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 30, 2026, 7:45 PM EDT